Pete Hegseth’s Fiery Capitol Hill Showdown: Senators Grill Him on $90 Billion Iran War Budget

Defense Secretary Pete Hegseth has ignited a fresh political firefight after unveiling a nationwide program that will screen all active-duty service members age 30 and older for “testosterone deficiency,” with younger troops allowed to opt in. Announced in a social-media video and formalized in a July 15 memo, the plan folds hormone testing into the Pentagon’s annual physicals and offers voluntary testosterone-replacement therapy, a move Hegseth says will keep forces “strong, resilient and capable” on modern battlefields. Supporters inside the Trump administration call the initiative an overdue step toward maximizing combat readiness and reducing fatigue, injuries and mood-related attrition. Health Secretary Robert F. Kennedy Jr. is simultaneously pushing the FDA to relax prescribing limits on testosterone gels, patches and injections, arguing they can help reverse declining enlistment fitness and lift retention rates. Critics, however, say the science lags behind the rhetoric. Current medical guidelines advise against blanket hormone testing; testosterone levels fluctuate daily and should be confirmed with two morning blood draws before therapy is even discussed. Sen. Tammy Duckworth (D-Ill.), an Iraq War veteran, blasted the policy as “gender-affirming care for men” and demanded equivalent estrogen screenings for female troops, noting the military’s higher-than-average infertility rate. Rep. Chrissy Houlahan (D-Pa.) called the rollout proof that Hegseth “takes direction from the far corners of the manosphere,” while Navy physician groups warn that unnecessary hormone therapy could mask cardiac risks and complicate combat-zone logistics. The debate comes as Hegseth, a former Army National Guard officer and Fox News host, faces mounting scrutiny on Capitol Hill. Lawmakers already grilled him this month over a separate $90 billion supplemental request to replenish precision-guided munitions and harden bases against drone swarms. Republican hawks back his hard-charging style, but several GOP senators privately warn that the testosterone gambit could sap political capital needed for Iran war funding votes. Inside the ranks, reaction is mixed. Special-operations veterans recall a 2022 Navy SEAL trainee’s death that exposed rampant, largely unsupervised steroid use; they welcome standardized testing but worry that “optional” therapy will become an unofficial requirement for promotions. Female service members question why the Pentagon is prioritizing male hormones while cutting budget lines for fertility preservation and postpartum leave. What happens next? The Defense Health Agency is drafting protocols for on-base labs and telehealth follow-ups, aiming to launch pilot testing at Fort Bragg, Camp Pendleton and Kadena Air Base by October. Congress could still block funding in the upcoming National Defense Authorization Act, but Hegseth has signaled he may reallocate internal medical accounts if lawmakers balk. For now, the secretary is betting that promises of peak performance—bolstered by influencer-driven “Make America Healthy Again” messaging—will outweigh bipartisan skepticism. Whether troops truly gain a strategic edge, or Washington simply gains another culture-war flashpoint, will hinge on early data from those fall pilots and on whether testosterone turns out to be a battlefield force-multiplier or a political liability.